Patients with ALK -
positive lung tumors may be candidates for targeted therapies that can improve prognosis and decrease risk for side effects.
Not exact matches
In the group that received targeted treatment for ALK -
positive lung cancer, each category of
tumor reduction was associated with corresponding gains in PFS and OS.
«First - line immunotherapy treatment can improve survival for subset of
lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV
lung cancer patients with both complex
tumor mutations and PDL - 1
positive status respond to nivolumab.»
«The result was an extensive inhibition of
tumor growth and prevention of metastasis to the
lung in HER2 -
positive animal models of breast cancer,» notes Navasona Krishnan, Ph.D., a postdoctoral investigator in the Tonks lab who performed many of the experiments and is lead author on the paper reporting the results.
Such a
positive survival rate is encouraging considering that historically conventional RT resulted in poor
tumor control for patients with inoperable
lung cancer.